(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-1.31%) $81.55
(-3.60%) $1.957
(-2.56%) $2 297.30
(-3.94%) $26.57
(-1.63%) $945.80
(0.50%) $0.937
(1.15%) $11.11
(0.55%) $0.800
(0.12%) $93.41
-0.12% ¥ 8 580.00
Live Chart Being Loaded With Signals
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 966 000 |
Średni wolumen | 0.00 |
Kapitalizacja rynkowa | 703.28B |
EPS | ¥0 ( 2024-02-12 ) |
Następna data zysków | ( ¥-12.48 ) 2024-05-08 |
Last Dividend | ¥50.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 83.43 |
ATR14 | ¥533 134 202 (0.23%) |
Wolumen Korelacja
Taisho Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Taisho Pharmaceutical Korelacja - Waluta/Towar
Taisho Pharmaceutical Finanse
Annual | 2022 |
Przychody: | ¥301.38B |
Zysk brutto: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Przychody: | ¥301.38B |
Zysk brutto: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Przychody: | ¥268.20B |
Zysk brutto: | ¥163.83B (61.09 %) |
EPS: | ¥161.12 |
FY | 2021 |
Przychody: | ¥282.04B |
Zysk brutto: | ¥175.99B (62.40 %) |
EPS: | ¥166.84 |
Financial Reports:
No articles found.
Taisho Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥50.00 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥50.00 | 2010-03-29 |
Last Dividend | ¥50.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 27 | -- |
Total Paid Out | ¥1 320.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.76 | -- |
Div. Sustainability Score | 7.14 | |
Div.Growth Potential Score | 2.76 | |
Div. Directional Score | 4.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9760.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8835.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8285.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7673.T | Ex Dividend Junior | 2024-05-30 | Annually | 0 | 0.00% | |
6855.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6203.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4929.T | Ex Dividend Junior | 2024-03-18 | Annually | 0 | 0.00% | |
4099.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3315.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2384.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0263 | 1.500 | 9.47 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00838 | 1.200 | 9.72 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0104 | 1.500 | -0.996 | -1.494 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.04 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 87.55 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.572 | 1.000 | 3.80 | 3.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0590 | 1.000 | -0.819 | -0.819 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.319 | 0.800 | -1.209 | -0.967 | [0.5 - 2] |
Total Score | 7.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 83.52 | 1.000 | 1.665 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0104 | 2.50 | -0.640 | -1.494 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.166 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -24.40 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.197 | 1.000 | 7.58 | 0 | [0.1 - 0.5] |
Total Score | 2.76 |
Taisho Pharmaceutical
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej